14 medicines of Patanjali Ayurveda banned in Noida Regional Ayurvedic and Unani officer banned the sale of these medicines with immediate effect. | Ban on 14 medicines of Patanjali Ayurveda in Noida: Regional Ayurvedic and Unani officer banned the sale of these medicines with immediate effect – Noida (Gautambudh Nagar) News
The Noida administration has banned the sale of 14 Ayurvedic medicines of Divya Pharmacy and Patanjali Ayurveda Limited. The administration took this decision after the Supreme Court’s direction on July 9, in which it banned the sale of Patanjali Ayurveda Limited, founded by yoga guru Swami Ramdev.
,
Giving information about this, officials said that the Regional Ayurvedic and Unani Officer of Gautam Buddha Nagar issued instructions to ban 14 products. He said that this action has been taken after the orders of the State Drug Licensing Authority (Ayurvedic and Unani Services) of Uttarakhand. Let us tell you that on April 15, the Uttarakhand State Licensing Authority had issued an order to suspend the manufacturing license of 14 products of Patanjali Ayurveda Limited and Divya Pharmacy.
Here is the list of those 14 products
According to information provided by the District Information Office, all doctors and medical stores operating in the district have been asked to immediately stop the sale of these 14 listed products. These products include Shwasari Gold, Shwasari Vati, Broncom, Shwasari Pravahi, Shwasari Avaleha, Mukta Vati Extra Power, Lipidom, Madhu Grit, BP Grit, Madhunashini Vati Extra Power, Livamrit Advance, Livogrit, Eyegrit Gold and Patanjali Drishti Eye Drops.
The license was revoked
Regional Ayurvedic and Unani Officer, Gautam Budh Nagar, Dr. Dharmendra Kumar Kem said that ‘As per the order of State Drug Licenses Authority Ayurvedic and Unani Services Uttarakhand, the manufacturing license of 14 medicines included in the attached list of Divya Pharmacy and Patanjali Ayurveda Limited has been cancelled.’
Discover more from Divya Bharat 🇮🇳
Subscribe to get the latest posts sent to your email.